The Tipping Point: How clinically validated MRD testing is transforming patient management in colorectal cancer
Watch Video
Oncology
Resources related to tests that help detect circulating tumor DNA for molecular residual disease assessment.
-
-
Utilization of Circulating Tumor DNA in the Surveillance Setting
Gibbs JN, Dale PS, Weatherall AL. The American Surgeon. 2023
Read More
-
Correlation between variant allele frequency and mean tumor molecules with tumor burden in patients with solid tumors
Kalashnikova E, Aushev, VA, Malashevich AK, et al. Molecular Oncology. 2023
Read More
-
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer
Tsimberidou AM, Alayli FA, Okrah K, et al. Journal of Experimental Medicine. 2024
Read More
-
Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors
Hernando-Calvo A, Yang SYC, Vila-Casadesús M, et al. JCO Precis Oncol. 2024
Read More
-
Tumor-informed ctDNA assessment as a valuable prognostic and predictive biomarker in diffuse large B-cell lymphoma
Narkhede M, Tomassetti S, Iqbal M. Front. in Oncol 2024
Read More
-
Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma
Phillipps J, Nassief G, Morecroft R, et al. NPJ Precision Oncology. 2024
Read More
-
Early real-world experience monitoring circulating tumor DNA in resected early-stage non–small cell lung cancer
Martin T, Dinerman A, Sudhaman S, et al. J Thorac Cardiovasc Surg. 2024
Read More
-
Clinical significance of perioperative minimal residual disease detected by circulating tumor DNA in lung cancer patients with a long follow
Ohara S, Suda K, Sudhaman S, et al. JTO Cinical and Research Reports. 2024
Read More
-
ctDNA as an Adjunct to Posttreatment PET for Head and Neck Cancer Recurrence Risk Assessment
Lele SJ, Adilbay D, Lewis E, et al. Otolaryngology–Head and Neck Surgery. 2024
Read More
-
Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies
F. Recio, C.S. Scalise, P. Loar et al. Gynecologic Oncology. 2024
Read More
-
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
Verschoor YL, van de Haar J, van den Berg JG, et al. Nat Med. 2024
Read More
-
A phase Ib feasibility trial of response adapted neoadjuvant therapy in gastric cancer (RANT-GC)
Dayyani F, Smith BR, Nguyen NT, et al. Future Oncol. 2022
Read More
-
Multi-Institutional Study Evaluating the Role of Circulating Tumor DNA in the Management of Appendiceal Cancers
Belmont E, Bansal VV, Yousef MMG, et al. JCO Precis Oncol. 2024
Read More
-
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
Pant S, Wainberg ZA, Weekes CD, et al. Nat Med. 2024
Read More
-
Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer
Eckhoff AM, Kanu E, Fletcher A, et al. Ann. Surg. Oncol. 2024
Read More
-
The Sequencing Conundrum in Localized Pancreatic Adenocarcinoma— Progress or Passive Acceptance?
Pathak P, Weekes CD, Shroff RT. JAMA Oncol. 2024
Read More
-
Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer A Nonrandomized Controlled Trial
Cecchini M, Salem RR, Robert M, et al. JAMA Oncol. 2024
Read More
-
Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma
Botta G, Abdelrahim M, Drengler RL, et al. The Oncologist, 2024
Read More
-
Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinoma
Yoo C, Jeong H, Jeong JH, et al. J. Hepatol., 2024
Read More
-
Loading More...
